FluoGuide (OM:FLUO) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

FLUO Overzicht aandelen

FluoGuide A/S, een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling van geneesmiddelen voor chirurgische resultaten door kanker fluorescerend te maken in Denemarken.

Over het bedrijf

FLUO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Verhandeld tegen 81.3% onder onze schatting van de reële waarde

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( DKK1M )

Heeft minder dan 1 jaar cash runway

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( SEK551M )

+ 1 meer risico

FluoGuide A/S Concurrenten

Hamlet BioPharma

NGM:HAMLET B

SEK 729.8m

Oncopeptides

OM:ONCO

SEK 458.3m

Isofol Medical

OM:ISOFOL

SEK 424.8m

Medivir

OM:MVIR

SEK 324.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor FluoGuide
Historische aandelenkoersen
Huidige aandelenkoers	SEK 40.85
52 Week Hoogtepunt	SEK 91.80
52 Week Laag	SEK 36.50
Bèta	1.08
11 maand verandering	2.64%
3 maanden verandering	-2.74%
1 Jaar Verandering	-54.61%
33 jaar verandering	-57.45%
5 jaar verandering	586.55%
Verandering sinds IPO	637.36%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	FLUO	SE Biotechs	SE Markt
7D	-1.4%	-4.6%	-1.3%
1Y	-54.6%	26.9%	24.4%

Rendement versus industrie: FLUO presteerde slechter dan de Swedish Biotechs -sector, die het afgelopen jaar een rendement van 28.8 % opleverde.

Rendement versus markt: FLUO presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 25.1 % opleverde.

Prijsvolatiliteit

Is FLUO's price volatile compared to industry and market?
FLUO volatility
FLUO Average Weekly Movement	5.4%
Biotechs Industry Average Movement	9.2%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: FLUO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van FLUO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2018	8	Morten Albrechtsen	fluoguide.com

FluoGuide A/S, een biotechnologiebedrijf in een klinische fase, richt zich op de ontwikkeling van geneesmiddelen voor chirurgische resultaten door kanker fluorescerend te maken in Denemarken. De belangrijkste productkandidaat is FG001, dat zich in Fase IIa en IIb bevindt voor de behandeling van hooggradig glioom; Fase II klinische studie voor de behandeling van longkanker en hoofd-halskanker. Het bedrijf ontwikkelt ook FG002, dat zich in een preklinische fase bevindt en chirurgen in staat stelt om kanker van normaal weefsel te onderscheiden tijdens chirurgie door middel van een nieuwe uPAR-gerichte luminescentietechnologie.

FluoGuide A/S Samenvatting

Hoe verhouden de winst en inkomsten van FluoGuide zich tot de beurswaarde?
FLUO fundamentele statistieken
Marktkapitalisatie	SEK 555.95m
Inkomsten(TTM)	-SEK 55.62m
Inkomsten(TTM)	SEK 1.87m

297.5x

P/S-verhouding

-10.0x

Koers/Winstverhouding

Is FLUO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
FLUO resultatenrekening (TTM)
Inkomsten	DKK 1.22m
Kosten van inkomsten	DKK 0
Brutowinst	DKK 1.22m
Overige uitgaven	DKK 37.65m
Inkomsten	-DKK 36.43m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 28, 2024

Winst per aandeel (EPS)	-2.68
Brutomarge	100.00%
Nettowinstmarge	-2,976.06%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde FLUO op de lange termijn?

Bekijk historische prestaties en vergelijking

FLUO Overzicht aandelen

Beloningen

Risicoanalyse

FluoGuide A/S Concurrenten

NGM:HAMLET B

SEK 729.8m

OM:ONCO

SEK 458.3m

OM:ISOFOL

SEK 424.8m

OM:MVIR

SEK 324.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

Recent updates

New major risk - Financial position

Fluoguide A/S Announces Executive Changes

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma